LAUSR

Carhart-Harris, R., B. Giribaldi, R. Watts, M. Baker-Jones, A. Murphy-Beiner, R. Murphy, J. Martell, A. Blemings, D. Erritzoe, D. J. Nutt, et al. 2021. Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine 384 (15):1402–11. doi:10.1056/NEJMoa 2032994. Coulson, A. 2023. Lecanemab approved for use by US FDA. NeuroCentral, 19 Jan. https://www.neuro-central.com/ lecanemab-approved-for-use-by-us-fda/ (accessed 20 Feburary, 2023). Flanagan, T. W., and C. D. Nichols. 2018. Psychedelics as anti-inflammatory agents. International Review of Psychiatry 30 (4):363–75. doi:10.1080/09540261.2018. 1481827. Hall, W. D., and K. Humphreys. 2022. Is good science leading the way in the therapeutic use of psychedelic drugs? Psychological Medicine 52 (14):2849–51. Hallinan, C. M., and Y. A. Bonomo. 2022. The rise and rise of medicinal cannabis, what now? Medicinal cannabis prescribing in Australia 2017–2022. International Journal of Environmental Research and Public Health 19 (16): 9853. Makin, S. 2018. The amyloid hypothesis on trial. Nature 559 (7715):S4–S7. Ona, G., M. Kohek, and J. C. Bouso. 2022. The illusion of knowledge in the emerging field of psychedelic research. New Ideas in Psychology 67:100967. doi:10.1016/j.newideapsych.2022.100967. Palop, J. J., and L. Mucke. 2016. Network abnormalities and interneuron dysfunction in Alzheimer disease. Nature Reviews Neuroscience 17 (12):777–92. doi:10.1038/nrn. 2016.141. Peterson, A., E. A. Largent, H. F. Lynch, J. Karlawish, and D. Sisti. 2023. Journeying to Ixtlan: Ethics of psychedelic medicine and research for Alzheimer’s disease and related dementias. AJOB Neuroscience 14 (2):107–123. doi: 10.1080/21507740.2022.2148771. Smith, W. R., and P. S. Appelbaum. 2021. Two models of legalization of psychedelic substances: Reasons for concern. JAMA 326 (8):697–8. doi:10.1001/jama.2021. 12481. Viana, J. N. M., M. Bittlinger, and F. Gilbert. 2017. Ethical considerations for deep brain stimulation trials in patients with early-onset Alzheimer’s disease. Journal of Alzheimer’s Disease 58 (2):289–301. doi:10.3233/JAD161073.